Mentor Corporation Begins U.S. Phase 1 Study Of Its Botulinum Toxin Product For Spasmodic Torticollis/Cervical Dystonia

SANTA BARBARA, Calif.--(BUSINESS WIRE)--May 15, 2006--Mentor Corporation (NYSE:MNT - News), a leading supplier of medical products in the United States and internationally, today announced that it has initiated the Phase 1 study of its proprietary botulinum toxin type A product, focused on the therapeutic indication of the treatment of pain associated with adult onset spasmodic torticollis/cervical dystonia in the United States.